Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-12-402945
Filing Date
2012-09-25
Accepted
2012-09-25 13:29:24
Documents
2
Effectiveness Date
2012-09-25

Document Format Files

Seq Description Document Type Size
1 DEFA14A d417649ddefa14a.htm DEFA14A 24726
2 GRAPHIC g417649g95g45.gif GRAPHIC 3963
  Complete submission text file 0001193125-12-402945.txt   31624
Mailing Address 12270 WILKINS AVENUE ROCKVILLE MD 20852
Business Address 12270 WILKINS AVENUE ROCKVILLE MD 20852 301-770-3099
NABI BIOPHARMACEUTICALS (Filer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35285 | Film No.: 121108359
SIC: 2836 Biological Products, (No Diagnostic Substances)